NCT00141024View on ClinicalTrials.gov

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
HIV Infections
Interventions
BIOLOGICAL

EP HIV-1043

"Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials."

BIOLOGICAL

EP HIV-1090

DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.

Trial Locations (3)

21201

Project Brave HIV Vaccine CRS, Baltimore

94102-6033

San Francisco Vaccine and Prevention CRS, San Francisco

14642-0001

Univ. of Rochester HVTN CRS, Rochester

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00141024 - Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults | Biotech Hunter | Biotech Hunter